New insider Maersk-Moller Kimberly claimed ownership of 141,801 shares (SEC Form 3)
$MDXG
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 06/24/2024 |
3. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 62,383(1) | D | |
| Common Stock | 18,366 | D(2) | |
| Common Stock | 28,564 | D(3) | |
| Common Stock | 32,488 | D(4) | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Options | (5) | 03/01/2031 | Common Stock | 39,308 | $8.63 | D | |
| Explanation of Responses: |
| 1. This filing is made on behalf of a new executive officer to report their existing holdings of MiMedx Securities. |
| 2. Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years from the original grant date of March 2, 2022, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement. |
| 3. Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years from the original grant date of March 13, 2023, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement. |
| 4. Reflects grant of restricted stock units which vests fully on the third anniversary of the grant from the original grant date of March 1, 2024, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement. |
| 5. The options granted to the reporting person shall vest 25% on each anniversary of the grant date of March 1, 2024, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement. |
| Remarks: |
| /s/ William F. Hulse, as attorney-in-fact for Kimberly Maersk-Moller | 07/03/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||